Farmacología en atención estomatológica en menores de 19 años / Presence of Pharmacology in stomatologic care in children aged under 19

Se presenta una revisión bibliográfica actualizada basada en evidencias científicas del uso de antimicrobianos, antiinflamatorios, analgésicos, antisépticos bucales y medicina natural y tradicional en estomatología, realizada por Medline, Doyma y otras fuentes bibliográficas. Se reporta que más de la mitad de la población mundial consume en un momento de su vida algunos de estos fármacos, indicados por diferentes patologías de orígenes infecciosos, inflamatorios, incluso como tratamiento prevenivos y preoperatorios. La edad pediátrica constituye un grupo de difícil manejo terapéutico dada la inmadurez física, fisiológica (sistema pulmonar, cardiovascular, inmunológico y metabólico) y emocional, lo que exige que el uso de estas drogas requieren un conocimiento actualizado por parte del personal médico. En tal sentido, presentamos una revisión con el objetivo de exponer lo más actual sobre el uso de antibióticos, antiinflamatorios, analgésicos y antisépticos bucales en cuanto a farmacología para estomatólogos generales que brindan atención a menores de 19 años con afecciones estomatológicas(AU)

A updated bibliographic review is presented based on scientific evidences on use of antimicrobials, anti-inflammatory, analgesics agents, oral antiseptics and natural and folk medicine in Stomatology, performed by Medline Doyma, and other bibliographic sources. Authors reports that more than half of world population, in any moment of its life, has been a consumer of these drugs, prescribed from different pathologies of infectious, inflammatory nature, even as a preventive preoperative treatment. Pediatric age is a difficult therapeutic management group due to physical, physiological ( pulmonary, cardiovascular, immunologic, and metabolic system) and emotional immaturity, requiring that medical staff must to have a updated knowledge on use of these drugs. In this context, we presented a revision to expose the more updated features on use of antibiotics, anti-inflammatory, and oral antiseptics, as for a Pharmacology for general stomatologists giving care to children ages under 19 presenting with stomatologic affections(AU)

Farmacología en atención estomatológica en menores de 19 años / Presence of Pharmacology in stomatologic care in children aged under 19

Se presenta una revisión bibliográfica actualizada basada en evidencias científicas del uso de antimicrobianos, antiinflamatorios, analgésicos, antisépticos bucales y medicina natural y tradicional en estomatología, realizada por Medline, Doyma y otras fuentes bibliográficas. Se reporta que más de la mitad de la población mundial consume en un momento de su vida algunos de estos fármacos, indicados por diferentes patologías de orígenes infecciosos, inflamatorios, incluso como tratamiento prevenivos y preoperatorios. La edad pediátrica constituye un grupo de difícil manejo terapéutico dada la inmadurez física, fisiológica (sistema pulmonar, cardiovascular, inmunológico y metabólico) y emocional, lo que exige que el uso de estas drogas requieren un conocimiento actualizado por parte del personal médico. En tal sentido, presentamos una revisión con el objetivo de exponer lo más actual sobre el uso de antibióticos, antiinflamatorios, analgésicos y antisépticos bucales en cuanto a farmacología para estomatólogos generales que brindan atención a menores de 19 años con afecciones estomatológicas(AU)

A updated bibliographic review is presented based on scientific evidences on use of antimicrobials, anti-inflammatory, analgesics agents, oral antiseptics and natural and folk medicine in Stomatology, performed by Medline Doyma, and other bibliographic sources. Authors reports that more than half of world population, in any moment of its life, has been a consumer of these drugs, prescribed from different pathologies of infectious, inflammatory nature, even as a preventive preoperative treatment. Pediatric age is a difficult therapeutic management group due to physical, physiological ( pulmonary, cardiovascular, immunologic, and metabolic system) and emotional immaturity, requiring that medical staff must to have a updated knowledge on use of these drugs. In this context, we presented a revision to expose the more updated features on use of antibiotics, anti-inflammatory, and oral antiseptics, as for a Pharmacology for general stomatologists giving care to children ages under 19 presenting with stomatologic affections(AU)

Nonenzymatic glycosylation of poly-L-lysine: a new tool for targeted gene delivery.

The basic approach in targeted gene delivery relies on the formation of a complex between a vector and a molecule that will be selectively internalized by the target cells. In the case of hepatocytes, asialoglycoproteins are convenient targeting molecules because of the high affinity and avidity of the hepatocyte galactose receptor. In this system, poly-L-lysine is cross-linked to an asialoglycoprotein, and the resulting conjugate is complexed with the expression vector (DNA). The electrostatic binding between DNA and poly-L-lysine-asialoglycoprotein ensures delivery of the intravenously injected complex to the liver, where it is subjected to endocytosis by hepatocytes. However, the poly-L-lysine-asialoglycoprotein complexes tend to be unstable, of limited solubility and of fixed carbohydrate content. For these reasons we searched for a simpler alternative. We exploited the known capacity of reducing sugars to be reductively coupled to the epsilon-amino groups in proteins and used lactose to obtain poly-L-lysine with "exposed" galactose. Glycosylation with sodium cyanoborohydride at high pH in borate buffer is a simple, reproducible procedure. The "lactosylated" poly-L-lysine has proved very stable, highly soluble and easily bound to plasmids. In a set of experiments we compared the asialofetuin-poly-L-lysine vector complexes with lactosylated poly-L-lysine vector complexes by transfecting hepatoma cells (HepG2) in culture. For these experiments we used a pRc/cytomegalovirus eukaryotic expression vector containing a mutant TGF-beta 1 complementary DNA.(ABSTRACT TRUNCATED AT 250 WORDS)